A Cracked Piece of Metal Self-Healed in Experiment That Stunned Scientists
File this under 'That's not supposed to happen!'. In an experiment published in 2023, scientists observed a damaged section of metal healing itself. Though the repair was only on a nanoscale level, understanding the physics behind the process could inspire a whole new era of engineering.
A team from Sandia National Laboratories and Texas A&M University was testing the resilience of a small piece of platinum suspended in a vacuum using a specialized transmission electron microscope technique to pull the ends of the metal 200 times every second.
They then observed the self-healing at ultra-small scales in the 40-nanometer-thick wafer of metal.
Cracks caused by the kind of strain described above are known as fatigue damage: repeated stress and motion that causes microscopic breaks, eventually causing machines or structures to break.
Amazingly, after about 40 minutes of observation, the crack in the platinum started to fuse back together and mend itself before starting again in a different direction.
"This was absolutely stunning to watch first-hand," said materials scientist Brad Boyce from Sandia National Laboratories when the results were announced.
"We certainly weren't looking for it. What we have confirmed is that metals have their own intrinsic, natural ability to heal themselves, at least in the case of fatigue damage at the nanoscale."
These are exact conditions, and we don't know yet exactly how this is happening or how we can use it. However, if you think about the costs and effort required for repairing everything from bridges to engines to phones, there's no telling how much difference self-healing metals could make.
While the observation is unprecedented, it's not wholly unexpected. In 2013, Texas A&M University materials scientist Michael Demkowicz worked on a study predicting that this kind of nanocrack healing could happen, driven by the tiny crystalline grains inside metals essentially shifting their boundaries in response to stress.
Demkowicz also worked on this study, using updated computer models to show that his decade-old theories about metal's self-healing behavior at the nanoscale matched what was happening here.
That the automatic mending process happened at room temperature is another promising aspect of the research. Metal usually requires lots of heat to shift its form, but the experiment was carried out in a vacuum; it remains to be seen whether the same process will happen in conventional metals in a typical environment.
A possible explanation involves a process known as cold welding, which occurs under ambient temperatures whenever metal surfaces come close enough together for their respective atoms to tangle together.
Typically, thin layers of air or contaminants interfere with the process; in environments like the vacuum of space, pure metals can be forced close enough together to literally stick.
"My hope is that this finding will encourage materials researchers to consider that, under the right circumstances, materials can do things we never expected," said Demkowicz.
The research was published in Nature.
An earlier version of this article was published in July 2023.
A Fifth Force of Nature May Have Been Discovered Inside Atoms
Strange Radio Signals Detected Emanating From Deep Under Antarctic Ice
Light Squeezed Out of Darkness in Surprising Quantum Simulation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
- Study completion anticipated in mid-2026 with subsequent data readout and regulatory submissions for treatment of severe hypertriglyceridemia PASADENA, Calif., June 23, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025. "Completion of enrollment for the SHASTA-3, SHASTA-4, and MUIR-3 studies represent important milestones for plozasiran," said Bruce Given, M.D., Chief Medical Scientist at Arrowhead. "These studies bring us closer to generating the datasets needed to support potential global regulatory submissions for plozasiran as a treatment for severe hypertriglyceridemia, pending positive results. With a primary endpoint focused on triglyceride reduction at 12 months, we remain on track for study completion by mid-2026. Arrowhead's clinical development, clinical operations, and regulatory teams continue to execute complex global clinical studies with speed and precision. We owe the entire team involved a debt of gratitude for efficiently initiating these studies in 24 countries and enrolling approximately 2,200 patients. We're grateful to the investigators, caregivers, and patients for participating in these clinical studies, and we thank them for their trust in Arrowhead and in plozasiran." About Severe Hypertriglyceridemia Severe hypertriglyceridemia (SHTG) is characterized by triglyceride (TG) levels greater than 500 mg/dL, with the most severe form being familial chylomicronemia syndrome (FCS) where TGs typically exceed 880 mg/dL. SHTG significantly increases the risk of acute pancreatitis (AP), which can often include recurrent attacks requiring repeat hospital admissions and worsening outcomes. AP risk is proportional to the number, characteristics, and concentration of triglyceride rich lipoproteins (TRLs), particularly chylomicrons, and increases as TGs rise. Elevated TGs can also increase the risk of atherosclerotic cardiovascular disease (ASCVD). Limited treatment options exist to sustainably reduce TGs below guideline directed risk thresholds. About SHASTA-3 and SHASTA-4 Phase 3 Studies SHASTA-3 (NCT06347003) and SHASTA-4 (NCT06347016) are double-blind, placebo-controlled, Phase 3 studies to evaluate the efficacy and safety of plozasiran in adults with severe hypertriglyceridemia. Between the two studies, approximately 750 participants were randomized to receive 4 doses (once every 3 months) of 25 mg plozasiran or placebo. The primary endpoint is percent change in fasting serum triglyceride levels from baseline to month 12 compared to placebo. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension. About MUIR-3 Phase 3 Study MUIR-3 (NCT06347133) is a double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of plozasiran in adults with hypertriglyceridemia (TGs greater than 150 mg/dL and less than 500 mg/dL). Approximately 1,450 participants were randomized to receive 4 doses (once every 3 months) of 25 mg plozasiran or placebo. The primary endpoint is percent change in fasting serum triglyceride levels from baseline to month 12 compared to placebo. About Plozasiran Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism. APOC3 increases triglyceride levels in the blood by inhibiting breakdown of TRLs by lipoprotein lipase and uptake of TRL remnants by receptors in the liver. The goal of treatment with plozasiran is to reduce the level of APOC3, thereby reducing triglycerides and restoring lipids to more normal levels. In multiple clinical studies, investigational plozasiran has demonstrated reductions in triglycerides and multiple atherogenic lipoproteins in patients with familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (SHTG), and mixed hyperlipidemia. Plozasiran has been generally well tolerated to date with treatment emergent adverse events reported that generally reflect the comorbidities and underlying conditions of the study populations. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose that is proposed for marketing approval were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain. Plozasiran is being investigated in the SUMMIT program of clinical studies, including the PALISADE Phase 3 study in patients with FCS, the SHASTA studies in patients with SHTG, and the MUIR studies in patients with mixed hyperlipidemia. Plozasiran in the treatment of patients with FCS has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Medicinal Product Designation by the European Medicines Agency. Investigational plozasiran has been submitted for marketing authorization in treatment of FCS to multiple global regulatory authorities but has not been reviewed or approved to treat any disease. About Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "might," "will," "expect," "believe," "anticipate," "goal," "endeavor," "strive," "hope," "intend," "plan," "project," "could," "estimate," "potential," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding regulatory approval for and commercial launch of plozasiran; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on Contacts Arrowhead Pharmaceuticals, Anzalone, CFA626-304-3400ir@ Investors: LifeSci Advisors, LLCBrian Ritchie 212-915-2578britchie@ Media: LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@
Forbes
19 minutes ago
- Forbes
Women In Engineering: Climate Impact And The Call For More Equity
Engineer at solar station. As the world races to meet net-zero targets, the role of women engineers has never been more critical. Today we celebrate International Women in Engineering Day 2025, under the theme 'Together We Engineer.' Female engineers have been impactful in renewable energy systems, sustainable infrastructure. Women are designing, building, and maintaining the future of our planet. The Numbers Show That We Need More Women in Engineering According to a UNESCO Science Report, women account for just 28% of engineering graduates globally. In the United States, only 13.7% of the engineering workforce are women, according to an Engineer Choice report. The underrepresentation is stark, however there is a lot of effort being made to increase these numbers globally through STEM clubs and books that introduce girls to different STEM fields including engineering. There are also engineers in the sustainability space like Rose Mutiso, who is the Research Director at the Energy for Growth Hub, whose work bridges energy equity and climate resilience across Sub-Saharan Africa through tailored infrastructure and policy innovation. According to IRENA's 2023 report, over 13 million people worked in renewable energy in 2022, yet only 32% were women, and most of those were in non-technical roles. In order to accelerate climate solutions, we must increase female participation in core engineering and energy leadership positions as women bring a different perspective to the sector that they are involved in. The professionals designing solar microgrids, optimizing battery storage, and advancing hydrogen and geothermal systems are vital to our future, and women are excelling in these roles. They bring not just technical expertise, but also empathy-led design, community-centered solutions, and systems thinking. These qualities are essential for building resilient, inclusive, and sustainable infrastructure. A McKinsey & Company study found that companies with higher gender diversity had 36% more revenue from innovation compared to those who do not. Additionally women are also underrepresented at all levels of the corporate pipeline. Equity is not a checkbox, it is a catalyst for innovation. Women Moving from Recognition to Action Climate change is not gender neutral. According to the United Nations, 80% of people displaced by climate change are women, due to their disproportionate reliance on natural resources, caregiving roles, and limited access to economic and decision-making power. In low-income and rural communities, women are often responsible for food, water, and fuel collection, which are becoming increasingly scarce due to climate-related disasters. Coupled with this, these intersecting vulnerabilities compound the risk of climate-driven social and economic instability. As a result, climate action must therefore be inclusive by design, with policies and technologies that protect and empower the most affected. Companies, governments, and academia must invest in mentorship, scholarships, and structural reforms to ensure the pipeline of female talent not only opens but flows and thrives. On this International Women in Engineering Day, we should pause and honor the women already engineering change and commit to empowering the ones of the future because, together, we engineer not just systems but a sustainable future.
Medscape
19 minutes ago
- Medscape
2019 Valley Fever Cases Exceeded Official Numbers
TOPLINE: Coccidioidomycosis, or valley fever, constituted a considerable public health burden, with surveillance data capturing only a fraction of actual cases. In 2019, the true annual incidence was approximately 10-18 times higher than reported cases, totaling an estimated 273,000 cases and 900 coccidioidomycosis-related deaths nationwide. METHODOLOGY: Researchers assessed the annual burden of symptomatic coccidioidomycosis in the US using data reported to the National Notifiable Diseases Surveillance System (NNDSS) from January 1, 2019, to December 31, 2019, as inputs for their models. The analysis used multipliers from US public health surveillance that accounted for healthcare-seeking behavior, underdiagnosis, underreporting, and in-hospital mortality, based on literature review and expert opinion. Regional estimates were generated by categorizing states as high-endemic states (Arizona and California), low-endemic states (Nevada, New Mexico, Texas, Utah, and Washington), or states with unknown endemicity (all other states and Washington, DC). TAKEAWAY: An estimated 273,000 incident symptomatic coccidioidomycosis cases (95% credible interval [CrI], 206,000-360,000) occurred in 2019, with high-endemic states accounting for 125,000 cases (95% CrI, 94,000-165,000). The national incidence was calculated as 83 cases per 100,000 people (95% CrI, 63-110), with regional rates of 267 per 100,000 in high-endemic states, 102 per 100,000 in low-endemic states, and 44 per 100,000 in states with unknown endemicity. An estimated 23,000 coccidioidomycosis-associated hospitalizations (95% CrI, 18,000-28,000) occurred nationwide, with high-endemic states accounting for 12,000 cases (95% CrI, 10,000-14,000). Approximately 900 coccidioidomycosis-related deaths (95% CrI, 700-1100) were estimated nationwide in 2019. IN PRACTICE: 'Increased awareness nationwide is needed among clinicians and the general public, as patients with knowledge of coccidioidomycosis may be more likely to be diagnosed earlier than those unfamiliar with the disease,' the authors wrote. SOURCE: This study was led by Samantha L. Williams, MPH, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta. It was published online on June 3, 2025, in JAMA Network Open. LIMITATIONS: The NNDSS data, used as the primary model input, captured only cases from states where coccidioidomycosis was reportable, requiring approximations for nonreporting states. Several multiplier values relied on expert opinion and lacked validation due to limited data. This study also did not account for demographic, medical, or exposure-related risk factors or lifelong immunity. DISCLOSURES: This study did not receive any specific funding. Few authors reported receiving funds from the CDC. Additionally, three authors reported receiving financial aid from certain pharmaceutical organizations. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
